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Aims

Non-invasive assessment of stable chest pain patients is a critical determinant of resource utilization and clinical outcomes. Increasingly coronary computed tomography angiography (CCTA) with selective CCTA-derived fractional flow
reserve (FFRCT) is being used. The ADVANCE Registry, is a large prospective examination of using a CCTA and FFRCT
diagnostic pathway in real-world settings, with the aim of determining the impact of this pathway on decision-making,
downstream invasive coronary angiography (ICA), revascularization, and major adverse cardiovascular events (MACE).

...................................................................................................................................................................................................
Methods
A total of 5083 patients with symptoms concerning for coronary artery disease (CAD) and atherosclerosis on CCTA
were enrolled at 38 international sites from 15 July 2015 to 20 October 2017. Demographics, symptom status, CCTA
and results

and FFRCT findings, treatment plans, and 90 days outcomes were recorded. The primary endpoint of reclassification between core lab CCTA alone and CCTA plus FFRCT-based management plans occurred in 66.9% [confidence interval
(CI): 64.8–67.6] of patients. Non-obstructive coronary disease was significantly lower in ICA patients with FFRCT <_0.80
(14.4%) compared to patients with FFRCT >0.80 (43.8%, odds ratio 0.19, CI: 0.15–0.25, P < 0.001). In total, 72.3% of
subjects undergoing ICA with FFRCT <_0.80 were revascularized. No death/myocardial infarction (MI) occurred within
90 days in patients with FFRCT >0.80 (n = 1529), whereas 19 (0.6%) MACE [hazard ratio (HR) 19.75, CI: 1.19–326,
P = 0.0008] and 14 (0.3%) death/MI (HR 14.68, CI 0.88–246, P = 0.039) occurred in subjects with an FFRCT <_0.80.

...................................................................................................................................................................................................
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In a large international multicentre population, FFRCT modified treatment recommendation in two-thirds of subjects as compared to CCTA alone, was associated with less negative ICA, predicted revascularization, and identified
subjects at low risk of adverse events through 90 days.
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Introduction
Coronary computed tomography angiography (CCTA) has been
shown to be an effective non-invasive test in the diagnosis and treatment planning for patients with stable chest pain and suspected coronary artery disease (CAD).1–4 Coronary computed tomography
angiography is excellent at ruling out CAD, but its utility is diminished
by the limited ability to predict physiologically significant CAD as
defined by an abnormal invasive fractional flow reserve (FFR).5,6
Coronary computed tomography angiography-derived fractional
flow reserve (FFRCT) is a non-invasive physiological test that can assess flow limitation across coronary stenoses with high diagnostic accuracy and good correlation to invasive FFR.7 In addition, FFRCT has
been shown to reduce the incidence of negative referrals to invasive
coronary angiography (ICA) post-CCTA, thus increasing the eventual
revascularization rate.8–10 However, to date most of the data have
been limited to single centre populations and trial settings and
there remains concerns regarding the clinical application of FFRCT,
especially in areas of ‘greyzone’ uncertainty, where diagnostic
accuracy may be lower.
The Assessing Diagnostic Value of Non-invasive FFRCT in
Coronary Care (ADVANCE) registry was designed to observe the
‘real-world’ utility and impact of using FFRCT in a broad variety of
healthcare settings, geographical regions, and patient populations.
The study aimed to determine how the incremental information of
an anatomical combined with functional FFRCT would change clinical
decision-making, patient management, clinical outcomes, and resource utilization.

Methods
Patients being investigated for clinically suspected CAD with documented
atherosclerosis >30% degree stenosis (DS) on CCTA were prospectively
enrolled at 38 sites in Europe, North American, and Japan from 15 July
2015 to 20 October 2017. All subjects were clinically stable symptomatic
patients diagnosed with CAD by CCTA who met the following eligibility
criteria: age >18 years, ability to provide informed consent, and CAD
diagnosed on a diagnostic standard CCTA. Exclusion Criteria included:
poor quality CCTA, life expectancy <1 year, and an inability to comply
with follow-up requirements. All patients provided written informed consent following Institutional Review Board review and approval.
Demographics, symptom status, CCTA and FFRCT findings, treatment
plans, and clinical outcomes through 90 days were recorded.

Management strategies
The site investigators were asked to report an initial management plan
and treatment strategy based on CCTA alone for each subject in accordance with local guidelines for the practice and interpretation of CCTA.
The decision to further investigate CCTA results with FFRCT was

•

Invasive coronary angiography

.. directed by the physician interpreting the scan with a recommendation to
..
.. consider FFRCT for stenoses in the 30–90% range. All FFRCT analyses
.. were performed in a single centre (HeartFlow, Redwood City, CA, USA).
.. Once the FFR result was made available, the site investigators were
CT
..
.. asked to re-determine the treatment strategy based on the new informa.. tion of the CCTA combined with the locally interpreted FFRCT result.
..
with the
.. A positive FFRCT was deemed to be a value <_0.80 in accordance
.. previous published invasive and non-invasive literature.11 Subsequent
.. clinical management decisions such as revascularization or medical ther..
.. apy rested at the discretion of the referring physician. The registry did not
.. dictate interpretation or management decisions.
..
A core laboratory [Duke Clinical Research Institute (DCRI), Durham,
..
.. NC, USA] blinded to clinical information, symptom status, and outcomes,
.. reviewed all CCTA and declared an independent management plan based
..
.. on CCTA alone. Coronary computed tomography angiography-derived
.. fractional flow reserve analyses were then made available to the core lab,
..
.. who then re-determined the subject specific treatment strategy for each
.. patient based on the CCTA and FFRCT results. This involved adjudication
.. of vessel- and lesion-specific ischaemia, measuring the FFR 2 cm distal
CT
..
.. to focal lesions.
..
Management plan treatment strategies for both site and core labora..
.. tory consisted of the following options: (i) optimal medical therapy, (ii)
.. percutaneous coronary intervention (PCI), (iii) coronary artery bypass
.. grafting (CABG) surgery, or (iv) additional diagnostic testing required. If
..
.. revascularization was selected, vessel segments to be revascularized
.. were specified and the interpreter was asked to recommend either PCI
..
.. or CABG. In instances of high-risk anatomy such as; three-vessel disease,
.. or two vessel involving the left anterior descending (LAD) artery or left
.. main stem disease, a consensus reading of two reviewers determined the
..
.. appropriate revascularization strategy.
..
..
.. Study endpoints
.. The primary endpoint was the reclassification rate between CCTA alone
..
.. vs. CCTA and FFRCT-based management plans as determined by the
.. core laboratory. Secondary endpoints included: reclassification rate be..
.. tween CCTA-based and FFRCT-based management plans as determined
.. by the site; incidence of ICA demonstrating absence of obstructive CAD
.. (no coronary stenosis >50%); percutaneous and surgical revasculariza..
.. tion rates; and 90 days survival free from all cause or major adverse
.. cardiovascular events (MACE) inclusive of myocardial infarction (MI), all..
.. cause mortality or unplanned hospitalization for Acute Coronary
.. Syndrome (ACS) leading to revascularization. Event adjudication was per.. formed by an independent Clinical Events Committee using standard defi..
.. nitions, blinded to clinical, and computed tomographic data.
..
..
.. Statistical analysis
.. Continuous data are presented as mean (± standard deviation) or median
..
.. (interquartile range, IQR), categorical data as frequency and percentage.
.. Comparative statistics for net reclassification used the Mann–Whitney
..
.. and Kruskal–Wallis tests as appropriate. Unpaired t-test was used to
.. determine differences between anatomic severity and rates of positive
.. FFR Univariable and multivariable logistic regression models using stepCT.
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Table 1

Demographics, coronary artery disease risk factors, and symptom status
CTA only (n 5 346)

FFRCT (n 5 4737)

Total (n 5 5083)

Age (years)
Male gender

64.3 (11.1)
215 (62.1%)

66.1 (10.3)
3134 (66.2%)

66.0 (10.3)
3349 (65.9%)

Hypertension

210 (60.7%)

2835 (59.8%)

3045 (59.9%)

Diabetes mellitus
Hyperlipidaemia

99 (28.6%)
204 (59%)

1037 (21.9%)
2753 (58.1%)

1136 (22.3%)
2957 (58.2%)

Current smoking
Ex-smoker

46 (13.3%)
118 (34.1%)

797 (16.8%)
1615 (34.1%)

843 (16.6%)
1733 (34.1%)

Never smoked

....................................................................................................................................................................................................................

Smoking

141 (41.6%)

1973 (41.7%)

2117 (41.6%)

Unknown
Angina status

38 (11.0%)

352 (7.4%)

390 (7.7%)

Atypical
Typical

175 (50.6%)
41 (11.8%)

1727 (36.5%)
1025 (21.6%)

1902 (37.4%)
1066 (21.0%)

Non-cardiac pain

8 (2.3%)

297 (6.3%)

305 (6.0%)

Dyspnoea
None

34 (9.8%)
73 (21.1%)

472 (10.0%)
1164 (24.6%)

506 (10.0%)
1237 (24.3%)

Unknown

15 (4.3%)

52 (1.1%)

67 (1.3%)

CCS angina class
Grade 1

18 (43.9%)

254 (24.8%)

272 (25.5%)

Grade II

16 (39.0%)

561 (54.7%)

577 (54.1%)

Grade III
Grade IV

5 (12.2%)
0

111 (10.8%)
23 (2.2%)

116 (10.9%)
23 (2.2%)

Unknown

2 (4.9%)

76 (7.4%)

78 (7.3%)

51.6 (±20.3)

160 (3.1%)
51.3 (±20.3)

CCTA rejection rate
Diamond–Forrester risk

46.8 (±19.9)

CTA, computed tomography angiography.

wise selection were used to estimate the odds of revascularization where
a P-value <0.1 was used for entry into the multivariable model. The fit of
the final model was assessed using the Log Likelihood and Akaike
Information Criterion. The v2 test of independence was used to assess if
negative catheterization and MI/death were independent of or associated
with minimum FFRCT strata (>0.8/<_0.8); in cases of low (expected cell
count <5) or zero cell counts, the Fisher’s exact test was used. Odds ratios
(ORs) and associated 95% confidence intervals (CIs) were calculated; in
cases of zero cell counts, relative risk and associated 95% CIs were calculated. A two-sided level of P < 0.05 was considered significant.

Study funding, design, data gathering, and
analysis
The ADVANCE Registry was funded by HeartFlow Inc., via individual
Clinical Study Agreements with each enrolling institution and with the
DCRI for Core Laboratory activities and Clinical Event Committee adjudication of adverse events. The trial database was housed in iMedNet.
HeartFlow and the independent Clinical Research Organization (CRO)
had access to iMedNet on the sponsor side. Principal Investigators, subinvestigators, and study co-ordinators at each site had access to iMedNet
and were responsible for data entry. The Clinical Event Adjudication and
core lab databases were housed in iMedNet. Duke Clinical Research
Institute had access to this data for entry, resolving queries, and locking
data. The CRO was able to query this data. HeartFlow did not have access
to adjudication forms. The primary analysis was performed by the Principal

.. Investigators including Drs Patel, Leipsic, Nieman, and Akasaka, as well as
..
.. by Dr Fairbairn, with statistical and analytical support from Dr Rogers and
.. Ms Mullen. The manuscript was drafted by the Principal Investigators and
..
.. Dr Fairbairn. All authors reviewed the manuscript and approved of the
.. submitted manuscript.
..
..
..
..
.. Results
..
..
.. Demographic, risk, and coronary artery
..
.. disease risk factor distribution
.. Patient demographics and distribution of CAD computed tomog..
.. raphy angiography (CTA) findings are provided in Table 1. A total of
.. 5083 patients were enrolled, of whom 4893 had CCTA submitted
..
.. for FFRCT (96.2%). A total of 190 subjects did not have their CCTA
.. examinations submitted for FFRCT analysis at the site discretion: 111
..
.. because the invasive treatment decision was made due to the severity
.. of the stenosis; 61 owing to minimal CAD; 9 because of multiple cor..
.. onary stents; 2 because of CCTA exams not acquired in a fashion ac.. ceptable for FFRCT analysis. Of the submitted CCTAs 4737 (96.8%)
..
.. were of adequate quality for analysis. 3.2% were rejected from FFRCT
.. analysis because of image quality. Angina (typical or atypical) was the
..
.. predominant symptom in 58%, with an average Diamond–Forrester
.. pre-test probability for obstructive coronary disease of 51.6%. There
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Figure 1 Degree of coronary artery disease (% stenosis) and coronary computed tomography angiography-derived fractional flow reserve positive/negative ratio stratified by coronary artery territory: (A) left anterior descending; (B) left circumflex, and (C) right coronary artery.
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Figure 2 Clinical management strategies and reclassification of post-coronary computed tomography angiography, following coronary computed
tomography angiography-derived fractional flow reserve and actual management at 90 days (A Core and B Site).

Table 2

FFRCT-determined treatment plan and actual clinical management at 90 days

Actual treatment

Site-determined post-FFRCT treatment plan

..........................................................................................................................
Revascularization
(n 5 1418)

Medications
(n 5 2679)

Further diagnostics
(n 5 121)

Total
(n 5 4737)

MT

504 (35.5%)

2545 (95.0%)

92 (76.0%)

3573 (75.4%)

PCI
CABG

799 (56.3%)
115 (8.1%)

115 (4.3%)
19 (0.7%)

25 (20.7%)
4 (3.3%)

1015 (21.4%)
149 (3.1%)

....................................................................................................................................................................................................................

Table 3 Actual treatment at 90 days (medical therapy vs. revascularization) stratified by coronary computed tomography angiography-derived fractional flow reserve values (0.05 increments)
Actual treatment

Site-determined post-FFRCT treatment plan

.............................................................................................................................................................................
<0.71
(n 5 1530)

0.71–0.75
(n 5 615)

0.76–0.8
(n 5 1000)

0.81–0.85
(n 5 867)

0.86–0.9
(n 5 595)

>0.9
(n 5 130)

Total
(n 5 4737)

Medical treatment

709 (46.3%)

468 (76.1%)

874 (87.4%)

820 (94.6%)

578 (97.1%)

124 (95.4%)

3573 (75.4%)

Revascularization

821 (53.7%)

147 (23.9%)

126 (12.6%)

47 (5.4%)

17 (2.9%)

6 (4.6%)

1164 (24.6%)

....................................................................................................................................................................................................................

was no significant difference between subject group demographics or
risk factors for those receiving CCTA alone vs. CCTA plus FFRCT.

Extent and severity of coronary artery
disease by coronary computed
tomography angiography and coronary
computed tomography angiographyderived fractional flow reserve
Coronary atheroma >_50% DS was observed at CCTA in 72.1% of
subjects (n = 3398) and >70% DS in 32% (n = 1538). Two- or threevessel disease (>_50% DS) was present in 27.5% and 9.4%,

..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..

respectively. Ischaemia (FFRCT <_0.80) in at least one coronary
territory was present in 61.9% (n = 3145) of patients (Figure 1).
The LAD was more likely to have anatomically severe (>70% DS),
coronary disease (21.4%), and a positive FFRCT (n = 2760, 58.3%)
compared with other vessels: left circumflex (LCX) 23.8% (n = 1260),
right coronary artery (RCA) 22.1% (n = 1047) (P < 0.001). The
LAD exhibited significantly lower median FFRCT values (0.79: IQR
0.71–0.85) compared with the LCX (0.88: IQR 0.81–0.92) and
RCA (0.87: IQR 0.82–0.91), (P < 0.001). However, a positive
FFRCT in the mild-moderate (30–70%) stenosis range was more
likely in the LAD (55.3%) compared with LCX (31.7%) and RCA
(27.3%), (P < 0.001).
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Figure 3 Actual treatment at 90 days (medical therapy, percutaneous intervention, and coronary bypass grafting) by post-coronary computed
tomography angiography-derived fractional flow reserve treatment strategy.

Figure 4 Actual treatment at 90 days (medical therapy, percutaneous intervention, and coronary bypass grafting) stratified by coronary computed
tomography angiography-derived fractional flow reserve values (0.05 increments).

Recommended clinical management
strategies following coronary computed
tomography angiography-derived fractional flow reserve
Coronary computed tomography angiography-derived fractional
flow reserve resulted in revision of the clinical management plan as
determined by the site investigators in 63.5% of patients (CI: 62.0–
65) when compared with initial CCTA-based treatment plan. Under
core laboratory analysis, FFRCT changed management plans in 66.9%
of patients (CI: 64.8–67.6). Reclassification patterns are shown in

..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.

Figure 2. Of 2386 (59.7%) patients in whom further information was
required after CCTA, FFRCT reclassified 70.0% (n = 1671) to medical
treatment (MT), 24.4% (n = 570) to PCI, 2.1% (n = 49) to CABG, and
only 2.6% (n = 121) were assigned to downstream testing. An initial
management decision for MT was assigned to 19.2% (n = 790), and
this assignment remained unchanged after FFRCT in 93% of cases,
with only 5.4% changing to revascularization (Table 2 and Figure 3).
However, among the 22.9% of subjects (n = 943) for whom the
CCTA-based management plan indicated revascularization, 22.3%
were reclassified to MT alone after FFRCT analysis (PCI to MT 20.9%,
n = 198; CABG to MT 1.4%, n = 12). A positive FFRCT (<_0.80)
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occurred in 61.9% of subjects, yet only 34.4% (site) and 46.8% (core)
of cases were recommended for revascularization despite the majority of these patients, 69.5% (n = 984) having anatomically significant
disease (>50% DS) on CCTA. Over half of the deferrals from ICA,
53.9% (n = 762) had an FFRCT between 0.75 and 0.8, with patients
with lower FFRCT more likely to be recommended for ICA (Table 3).

Table 4 Multivariable logistic regression analysis of
univariate predictors of revascularization amongst subjects with coronary computed tomography angiography-derived fractional flow reserve performed as
compared to those subjects who did not undergo
revascularization
Covariates

Rate of non-obstructive angiography and
revascularization

In this large prospective international multicentre registry, FFRCT
changed management recommendations from CCTA-based plans in
approximately two out of three subjects. A negative FFRCT was associated with a low rate of invasive angiography or revascularization
within 90 days and with freedom from MI or death. In addition, there
was an inverse relationship between FFRCT and the likelihood of
downstream ICA, revascularization, and MACE.
Coronary computed tomography angiography is now considered
a reasonable or preferred first line investigation for patients with suspected CAD,12–14 as studies have suggested improved clinical outcomes for patients managed based on initial CCTA rather than
alternative non-invasive tests.4 While, CCTA has been proven to be
an effective diagnostic tool, there remain concerns regarding fairly
high rates of downstream ICA and resource utilization as well as the
lack of physiological information available to guide treatment decision-making.2,15,16 FFRCT has been proposed as a diagnostic tool to
help determine more appropriately who should proceed for ICA following CCTA.7,8,15,17 The PROMISE FFRCT retrospective sub-study

P-value

Age (>_65)

-0.0433

0.96 (0.81–1.14)

0.6189

Female gender
Hyperlipidaemia

-0.2953
0.3036

0.74 (0.62–0.90)
1.35 (1.14–1.61)

0.0023
0.0005

Diabetes mellitus

0.0990

1.10 (0.91–1.33)

0.3066

Smoking
Symptom status

0.1150

1.12 (0.89–1.41)

0.3189

Typical angina

0.9898

2.69 (2.14–3.38) <0.0001

Atypical angina
Non-cardiac pain

0.2808
0.1223

1.32 (1.06–1.61)
1.13 (0.76–1.89)

0.0129
0.5400

Dyspnoea

0.3204

1.38 (1.00–1.89)

0.0472

1.7666
1.8959

5.85 (4.95–6.91) <0.0001
5.88 (4.43–7.80) <0.0001

Coronary stenosis >70%
FFRCT <_0.8

Intercept parameter estimate: -3.8806, P < 0.0001. Reference categories for covariates: (i) age: ‘<_65 years’, (ii) ‘male sex’, (iii) ‘no hyperlipidaemia’, (iv) ‘no diabetes
mellitus’, (v) ‘no smoking’, (vi) no ‘typical angina’, ‘atypical angina’, ‘non-cardiac
pain’, or ‘dyspnoea’, (vii) coronary stenosis: ‘<_70%’, and (viii) FFRCT: ‘>0.8’.

Major adverse cardiovascular events,
myocardial infarction, and death

Discussion

Odds ratio

.................................................................................................

The rate of anatomically defined ‘non-obstructive’ disease at ICA (no
stenosis >50% at ICA) was significantly lower in patients with FFRCT
<_0.80 (14.4%) vs. FFRCT >0.80 (43.8%), (OR 0.19, CI 0.15–0.25,
P < 0.001) (Figure 3).
When stratified by 0.05 categorical FFRCT increments, subjects
were significantly more likely to undergo ICA with decreasing FFRCT
(FFRCT <_0.70: 73.8% vs. FFRCT >0.80: 20.5%) and to be revascularized at ICA (FFRCT <_0.70: 72.5% vs. FFRCT >0.80: 20.4% P < 0.001),
(Supplementary material online). In multivariable analysis, stenosis
>70%/occluded vessel (OR 5.85–6.36, P < 0.00105) and FFRCT <0.80
(OR 5.88, P < 0.001) were significant predictors of revascularization
(Table 4 and Figure 4), as were the presence of typical/atypical symptoms and male gender.

No death or MI occurred within 90 days in any subject whose FFRCT
was >0.80 (n = 1592). Conversely, in patients with at least one FFRCT
value <_0.80 (n = 3145) there were 19 (0.6%, P < 0.01) MACE events;
4 MI, 5 urgent unplanned hospitalizations for ACS and urgent revascularization and 10 deaths. These events predominantly occurred in
the lower FFRCT ranges below 0.76 (18 of 19), indicating that an
FFRCT <_0.80 increased the risk of an adverse event [MACE, hazard
ratio (HR) 19.75, CI 1.19–326], P = 0.0008 and 14 death/MI, HR
14.68, CI 0.88–246, P = 0.039], (Figure 5A and B).

Estimates
of effect
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highlighted the potential of FFRCT to reduce ICA referral and enrich
the appropriateness of the population referred for ICA.17,18
Our findings based on prospective utilization of FFRCT after positive CCTA represent the first real-world multicentre evaluation of
the utility and safety of FFRCT. FFRCT led to a recommendation of
ICA in only 40% of subjects in a cohort with an anatomic obstructive
disease rate of 72%, and subjects referred for ICA downstream were
significantly more likely to have obstructive disease at ICA if they had
a positive FFRCT.19–21
Management reclassification by FFRCT as expected occurred in all
directions. There was, however, a clear directed benefit in instances
of physician uncertainty expressed by the need for ‘further testing’, as
the majority of subjects (70%) were safely deferred to medical management alone. Importantly only in a very small minority of cases (0%
by core lab and 2.6% by site) was further testing deemed necessary
to determine CAD significance, thereby highlighting the improved
diagnostic certainty and the opportunity to reduce further downstream testing. Importantly, this approach of test layering not only
results in increased costs and at times additional radiation exposure,
it may not help discriminate those patients likely to benefit from
revascularization. In the recently published PACIFIC trial, hybrid testing with a CTA/SPECT approach did not enhance on the accuracy
for the detection of lesions specific ischaemia beyond CCTA or
SPECT alone.22 In instances, when the physician recommendation
was for revascularization post-CCTA alone, FFRCT redirected management to medical therapy in close to 25% of cases, offering the potential to avoid unnecessary ICA. This observation supports the
concept that CCTA alone could result in increased ICA without
revascularization.6 Interestingly a positive FFRCT (<_0.80) was not
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Figure 5 Major adverse cardiac events (A) (all-cause mortality, myocardial infarction, unplanned hospitalization with urgent revascularization) and
(B) myocardial infarction/all-cause mortality alone at 90 days for coronary computed tomography angiography-derived fractional flow reserve positive (<_0.80) and negative values (>0.80).

followed by either ICA or revascularization in up to half of cases, despite the majority having evidence of anatomical (>50% DS) significant
disease. This perhaps reflects nuanced management decisions
regarding factors such as diffuse atherosclerosis and the absence
of lesion specific ischaemia or other factors such as anatomical location, comorbidities, and symptom severity. It is also important
to recognize that follow-up is limited to 90 days at present and
longer term follow-up will be valuable to assess whether these
medically managed FFRCT-positive patients will end up needing
revascularization over time is uncertain. These findings should
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..
..
..
..
..
..
..
..

also be placed into the context of recent guidelines highlighting
the importance of guiding revascularization decision-making based
on anatomy and physiology emphasizing the value of FFRCT to
enable meaningful Heart Team discussions in a fashion that CTA
alone cannot.23,24
There is also growing awareness that while in a trial setting FFR
and FFRCT have been evaluated using a binary cut-off, in practice the
benefit from revascularization seems to increase with lower FFR values.21,25,26 Predictors of revascularization in this study were lesion
specific ischaemia by FFRCT, diameter stenosis >_70% and angina
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Figure 6 Three-dimensional coronary computed tomography angiography-derived fractional flow reserve pressure model of (A) a 59-year-old
male with a 50–70% mid left anterior descending coronary artery stenosis yet severe ischaemia (coronary computed tomography angiographyderived fractional flow reserve <_0.50) who experienced an NSTEMI in follow-up. (B) In comparison, a 71-year-old male with a more severe stenosis
(70–90%) in the mid-left anterior descending without lesion specific ischaemia (coronary computed tomography angiography-derived fractional flow
reserve 0.83) who was clinically well through 90 days follow-up.

symptoms. FFRCT, like all test results, needs to be integrated into the
overall clinical presentation including severity of symptoms. There
was a difference noted between site and core management plans in
the setting of positive FFRCT, with site management strategies being
more conservative in recommending ICA and revascularization
(34.4%), supporting the theory that there is a significant role in the interpretation and clinical context of the FFRCT result, as sites were
privy to greater information of the clinical history and co-morbidities
whereas the core lab was not.
This international real-world registry has also highlighted patterns
of physician referral behaviour. The majority of lesions referred for
further investigation were in the LAD, which is greater than the
observed proportions of LAD disease burden in ICA studies,19 and
likely reflects heightened clinical concerns owing to the prognostic
importance of LAD disease. The varied correlation between degree
of stenosis and ischaemia is well known from studies such as FAME
and RIPCORD,27,28 which may result in a higher degree of uncertainty and desire to know more information. The increased likelihood
of FFRCT-determined ischaemia in the mild-moderate (30–70%) degree of anatomical stenosis in the LAD compared to other vessels is
of particular diagnostic use and given the high frequency in our patient population (55.3%), justifies clinicians’ vigilance in referring these
lesions to ICA.24,25
Beyond defining the clinical use and role of FFRCT, our data provide
meaningful insight into the potential prognostic value of FFRCT in clinical practice. Importantly, a negative FFRCT was associated with an excellent short-term prognosis, as none of the 1592 subjects with negative
FFRCT experienced death, MI, or unplanned hospitalization for ACS
and urgent revascularization. All MACE events occurred in subjects
with FFRCT <_0.80, with the majority of events in subjects with an
FFRCT <_0.75. This clustering of events in subjects with more significant
ischaemia is interesting, however, long-term clinical follow-up is
needed to determine if there is a relationship between the severity of
FFRCT reduction and adverse clinical outcomes. Our results mirror the
invasive physiology experience where lower FFR values have been

..
.. consistently shown to predict all-cause mortality and increased likeli.. hood of MI and urgent revascularization.29
..
..
.. Limitations
..
.. Our analysis is not without limitations. To start, while including a
.. broad sampling of patients undergoing FFR across many countries
CT
..
.. and healthcare systems, ADVANCE is a registry, and therefore, we
.. cannot exclude some element of referral bias. As well, while sites
..
.. provided their treatment strategies on the basis of CCTA, virtually all
..
.. subjects had FFRCT available and therefore what their downstream
.. treatment would have been in absence of FFRCT cannot be deter..
.. mined with complete certainty. As such, while we report the change
.. in clinical recommendations following FFRCT as compared to CCTA
..
.. alone, through 90 days not all site recommendations were followed
.. clinically, highlighting the multifaceted nature of clinical decision-mak..
.. ing. In addition, while detailed case/incident reports were submitted
.. detailing all events, like many registries, a central event adjudication
..
.. committee was not used. Finally, the Follow-up reported represents
.. only the first 90 days, and although most adverse events and invasive
..
.. management strategies occur within this time, longer term follow-up
.. is essential particularly for MACE, and therefore is planned through 3
..
.. years in the ADVANCE registry.
..
..
..
.. Conclusions
..
..
.. In a large international multicentre population, FFRCT-modified treat.. ment recommendation in up to two-thirds of subjects as compared
..
.. to CCTA alone, was associated with fewer ICA without obstructive
.. disease, and predicted revascularization, while helping discriminate
..
.. subjects at lower risk of adverse events at 90 days.
..
..
..
.. Supplementary material
..
.. Supplementary material is available at European Heart Journal online.
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